Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium that have become resistant to many commonly used antibiotics. While it is a treatable infection, it is a significant public health issue. S. aureus (commonly referred to as "staph") is a common type of bacteria that normally lives on the skin or in the nasal passages of healthy people.
MRSA THERAPEUTICS UNDER DEVELOPMENT (2018)
Certain strains of the bacteria that resist the usual antibiotics given to fight staph infections are known as MRSA. Infection can occur when these bacteria enter the body through cut, sore, catheter or breathing tubes. Such infections range from minor such as a pimple, to serious involving the heart, lungs, bloodstream or bones.
The majority of drug candidates has received funding by the various organizations such as Small Business Innovation Research (SBIR) and National Health Service (NHS) that are incentivizing research and development of novel antibiotics for the treatment of MRSA infection. Also, various designations have been awarded to the MRSA drug candidates that speed up the research process involved in the drug development. It has been observed that drug designations such as Qualified Infectious Disease Products designation, Fast track and priority review status, speeding up the process from Phase I to NDA filing are supporting the growth of the MRSA infection therapeutics pipeline.
As of February 2018, the MRSA therapeutics pipeline comprises of 52 drug candidates in different stages of development.
Some of the key players involved in the development of MRSA therapeutics include GlaxoSmithKline plc, Crystal Genomics Inc., and Innovation Pharmaceuticals Inc.